Immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients with primary brain tumors: a prospective cohort study.

Amir MassarwehRoi TschernichovskyAmos StemmerAlexandra Benouaich-AmielTali SiegalNoa Eliakim-RazSalomon M StemmerShlomit Yust-Katz

Published in: Journal of neuro-oncology (2022)

Most PBT patients successfully seroconvert following two doses of the BNT162b2 vaccine, albeit with lower antibody titer compared to HCs. Steroid use during the vaccination period is associated with lower titer.

Keyphrases

end stage renal disease
coronavirus disease
ejection fraction
sars cov
newly diagnosed
chronic kidney disease
prognostic factors
patient reported outcomes
patient reported
respiratory syndrome coronavirus
binding protein